Market Research Logo

Constipation - Pipeline Review, H1 2015

Constipation - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Constipation - Pipeline Review, H1 2015’, provides an overview of the Constipation’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Constipation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Constipation and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Constipation
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Constipation and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Constipation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Constipation pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Constipation
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Constipation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Constipation Overview
Therapeutics Development
Pipeline Products for Constipation - Overview
Pipeline Products for Constipation - Comparative Analysis
Constipation - Therapeutics under Development by Companies
Constipation - Therapeutics under Investigation by Universities/Institutes
Constipation - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Constipation - Products under Development by Companies
Constipation - Products under Investigation by Universities/Institutes
Constipation - Companies Involved in Therapeutics Development
AlbireoPharma
Astellas Pharma Inc.
AstraZeneca PLC
Beech Tree Labs, Inc.
Braintree Laboratories, Inc.
Daiichi Sankyo Company, Limited
Dong-A Socio Group
Ironwood Pharmaceuticals, Inc.
Kissei Pharmaceutical Co., Ltd.
Lipid Pharmaceuticals ehf.
Rhythm Pharmaceuticals
Sanwa Kagaku Kenkyusho Co., Ltd.
Shire Plc
SK Biopharmaceuticals Co., Ltd.
Sucampo Pharmaceuticals, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Synergy Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited
Constipation - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
5-BOIP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASP-7663 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BLI-801 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DA-6886 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DS-3801 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DSP-6952 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
elobixibat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KWA-0711 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
linaclotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LP-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lubiprostone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDT-006 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
plecanatide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
prucalopride succinate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
relamorelin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SK-1202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Chronic Constipation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tenapanor hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Transilon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YKP-10811 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Constipation - Recent Pipeline Updates
Constipation - Dormant Projects
Constipation - Product Development Milestones
Featured News & Press Releases
Nov 20, 2014: Ironwood Earns $15 Million Milestone from Astellas upon Initiation of Enrollment in Linaclotide Phase III IBS-C Clinical Trial in Japan
Nov 12, 2014: Sucampo Files Patent Infringement Lawsuit Against Dr. Reddy's
Nov 04, 2014: Ironwood Pharmaceuticals Initiates Phase III Trial of 72 mcg Linaclotide in Adult Patients with Chronic Idiopathic Constipation
Oct 24, 2014: Rhythm Presents Positive Phase 2 Study Results for Relamorelin for Chronic Constipation
Oct 13, 2014: Clinical Data for AMITIZA Lubiprostone to be Presented at the American College of Gastroenterology 2014 Annual Scientific Meeting
Oct 09, 2014: Sucampo Announces Settlement Agreement That Resolves Patent Litigation in U.S. Related to AMITIZA
Sep 18, 2014: Synergy Pharmaceuticals Reaches Halfway Mark for Second Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation
Aug 21, 2014: Sucampo Announces New Exclusive Global Manufacturing and Supply Agreement for Lubiprostone
Jul 14, 2014: Synergy Pharmaceuticals Reaches Halfway Mark for the First Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation
May 06, 2014: Rhythm Presents Positive GI Motility Results for Relamorelin (RM-131) in Phase 2 Chronic Constipation Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Constipation, H1 2015
Number of Products under Development for Constipation - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Constipation - Pipeline by AlbireoPharma, H1 2015
Constipation - Pipeline by Astellas Pharma Inc., H1 2015
Constipation - Pipeline by AstraZeneca PLC, H1 2015
Constipation - Pipeline by Beech Tree Labs, Inc., H1 2015
Constipation - Pipeline by Braintree Laboratories, Inc., H1 2015
Constipation - Pipeline by Daiichi Sankyo Company, Limited, H1 2015
Constipation - Pipeline by Dong-A Socio Group, H1 2015
Constipation - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2015
Constipation - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015
Constipation - Pipeline by Lipid Pharmaceuticals ehf., H1 2015
Constipation - Pipeline by Rhythm Pharmaceuticals, H1 2015
Constipation - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2015
Constipation - Pipeline by Shire Plc, H1 2015
Constipation - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015
Constipation - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2015
Constipation - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015
Constipation - Pipeline by Synergy Pharmaceuticals, Inc., H1 2015
Constipation - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Constipation Therapeutics - Recent Pipeline Updates, H1 2015
Constipation - Dormant Projects, H1 2015
List of Figures
Number of Products under Development for Constipation, H1 2015
Number of Products under Development for Constipation - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report